Skip to main content

XORTX Therapeutics Inc (XRTX)

NASDAQ: XRTX · IEX Real-Time Price · USD
1.99 -0.09 (-4.33%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap25.16M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out12.65M
EPS (ttm)-1.03
PE Ration/a
Forward PE1.38
Dividendn/a
Ex-Dividend Daten/a
Volume138,551
Open2.02
Previous Close2.08
Day's Range1.81 - 2.07
52-Week Range1.81 - 5.89
Beta0.24
Analystsn/a
Price Targetn/a
Earnings Daten/a

About XRTX

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor ...

IndustryBiotechnology
Founded2011
CEOAllen Davidoff
CountryCanada
Stock ExchangeNASDAQ
Ticker SymbolXRTX
Full Company Profile

Financial Performance

Financial Statements

News

XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative...

1 week ago - GlobeNewsWire

Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)  Click Here  to vi...

2 weeks ago - PRNewsWire

XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange

CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative...

1 month ago - GlobeNewsWire

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

CALGARY, Alberta, Nov. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative t...

1 month ago - GlobeNewsWire

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative t...

1 month ago - GlobeNewsWire

XORTX Announces Results from Mount Sinai's COVID-19 Clinical Study

Early, High Uric Acid is Independently Associated with Acute Kidney Injury and Mortality in COVID-19 Early, High Uric Acid is Independently Associated with Acute Kidney Injury and Mortality in COVID-19

1 month ago - GlobeNewsWire

XORTX to Present at the LD Micro Main Event

Virtual Corporate Presentation – October 14, 2021 – 10 am ET Virtual Corporate Presentation – October 14, 2021 – 10 am ET

1 month ago - GlobeNewsWire